Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1Gynecologic 1Genitourinary 1Classical hematology 1

Conditions

Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Small Cell Lung Carcinoma 1Head and Neck Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Anemia 1

Interventions

pembrolizumab 34Cisplatin 12Nivolumab 10atezolizumab 9Docetaxel 9Carboplatin 9Paclitaxel 8Cetuximab 8Gemcitabine 7Blood Specimen Collection 7Radiotherapy 6Fluorouracil 6Drug Therapy 6cemiplimab 5Pemetrexed 5Immune Checkpoint Inhibitors 5fludarabine 4Standard of Care 4Cyclophosphamide 4spartalizumab 3epacadostat 3Surveys and Questionnaires 3Oncolytic Virotherapy 3Nicotine 3Magnetic Resonance Spectroscopy 3Irinotecan 3Interleukin-2 3Filgrastim 3Bupropion 3Bortezomib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Head and Neck Neoplasms × ACE-011 × Thoracic × Clear all
NCT01284348 2024-08-29

To Determine Safe and Effective Dose of Sotatercept for the Treatment of Chemotherapy Induced Anemia in Participants With Advanced Non-small Cell Lung Cancer

Merck Sharp & Dohme LLC

Phase 2 Terminated
26 enrolled 18 charts
Classical hematologyGenitourinaryGynecologicHead & NeckThoracic

Anemia, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡